Formulation and evaluation of chitosan solid lipid nanoparticles of carbamazepine

Lipids in Health and Disease

Prasanna Y Raju¹  Chakrapani M Yadav¹  Vishnu K Priya¹  Ashok CK Kumar¹  Rahul Nair¹ 

[1] Department of Pharmaceutics, Sree Vidyanikethan College of Pharmacy, Sree Sainath Nagar, Tirupati-517102, Andhra Pradesh, India

关键词: Encapsulation efficiency;    Carbamazepine;    Chitosan;    Solid lipid nanoparticles;   

Others  :  1160283
DOI  :  10.1186/1476-511X-11-72

 received in 2012-03-22, accepted in 2012-05-23,  发布年份 2012

【 摘 要 】

The present work aims at preparing aqueous suspension of Solid lipid Nanoparticles containing Chitosan (CT) which is a biopolymer that exhibits a number of interesting properties which include controlled drug delivery. Carbamezapine (CBZ) is a lipophilic drug which shows it antiepileptic activity by inactivating sodium channels. The solid lipid Nanoparticles (SLN) of Chitosan-CBZ were prepared by using solvent injection method using ethanol as organic solvent. The prepared SLN formulations exhibited high encapsulation efficiency, high physical stability. The drug incorporated SLNs have demonstrated that the controlled release patterns of the drug for prolonged period. The prepared SLNs were characterized for surface morphology by SEM analysis, entrapment efficiency, zeta potential, FTIR, DSC and In-vitro diffusion studies. The hydrodynamic mean diameter and zeta potential were 168.7 ±1.8 nm and −28.9 ±2.0 mV for SLN-chitosan-CBZ respectively. Therefore chitosan-SLN can be good candidates to encapsulate CBZ and to increase its therapeutic efficacy in the treatment of Epilepsy.

【 授权许可】

   
2012 Nair et al.; licensee Biomed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

Figure 6.

【 参考文献 】

• [1]Zur Muhlen A, Schwarz C, Mehnert W: Solid lipid nanoparticles (SLN) for controlled drug delivery-drug release and release mechanism. Eur J Pharm Biopharm 1998, 45(2):149-155.
• [2]Cavalli R, Caputo O, Gasco MR: Solid lipospheres of doxorubicin and idarubicin. Int J Pharm 1993, 89(1):R9-R12.
• [3]Freitas C, Müller RH: Spray-drying of Solid lipid nanoparticles (SLNTM). Eur J Pharm Biopharm 1998, 46(2):145-151.
• [4]Domb AJ: Liposphere parenteral delivery system. Proc Intl Symp Control Rel Bioact Mater 1993, 20:346-347.
• [5]Zur Muhlen A: Feste Lipid-Nanopartikel mit prolongierter Wirkstoffliberation: Herstellung, Langzeitstabilitat, Charakterisierung, Freisetzungsverhalten and mechanismen. Ph.D. thesis. Free University of Berlin; 1996.
• [6]Eldem T, Speiser P, Hincal A: Optimization of spray-dried and congealed lipid microparticles and characterization of their surface morphology by scanning electron microscopy. Pharm Res 1991, 8:47-54.
• [7]Muller RH, Maabenb S, Weyhersa H, Spechtb F, Lucksb JS: Cytotoxicity of magnetite-loaded polylactide, polylactide/ glycolide particles and solid lipid nanoparticles. Int J Pharm 1996, 138(1):85-94.
• [8]Speiser P: Lipidnanopellets als Tragersystem fur Arzneimittel zur perolen Anwendung. 1990. European Patent, EP 0167825
• [9]Mehnert W, Mäder K: Solid lipid nanoparticles: production, characterization and applications. Adv Drug Deliver Rev 2001, 47(2–3):165-196.
• [10]Muller RH, Olbrich C, Kayser O: Lipase degradation of Dynasan 114 and 116 solid lipid nanoparticles (SLN) – effect of surfactants, storage time and crystallinity. Int J Pharm 2002, 237:119-128.
• [11]Muller RH, Maader K, Gohla S: Solid lipid nanoparticle (SLN) for controlled drug delivery-review of the state of the art. Eur J Pharm Biopharm 2000, 50:161-177.
• [12]Muller RH, Runge SA: Solid lipid nanoparticles (SLN) for controlled drug delivery. In Submicron Emulsions in Drug Targeting and Delivery. Edited by Benita S. Amsterdam: Harwood Academic Publishers; 1998:219-234.
• [13]Jenning V, Gysler A, Schafer-Korting M, Gohla S: Vitamin A loaded solid lipid nanoparticles for topical use: occlusive properties and drug targeting to the upper skin. Eur J Pharm Biopharm 2000, 49(3):211-218.
• [14]Katja H, Andreas H, Reinhard S: Chitosan-based transport system. 2005. US 2006/0051423 A1
• [15]Foreman JC, Johansen T: Textbook of Receptor Pharmacology. 2nd edition. Boca Raton, FL: CRC Press; 2002.
• [16]Ridolfia DM, Marcatoa PD, Justob GZ, Cordid L, Machadob D, Duran N: Chitosan-solid lipid nanoparticles as carriers for topical delivery of tretinoin. Colloids Surf B Biointerfaces 2012, 93(1):36-40.
• [17]Safal J, Sanjay J, Piush K, Arvind G, Divya BL, Sanjay KJ: Design and development of solid lipid nanoparticles for topical delivery of an anti-fungal agent. Drug Delivery 2010, 17(6):443-451.
• [18]Gulbake A, Jain A, Khare P, Jain SK: Solid lipid nanoparticles bearing Oxybenzone: in-vitro and in-vivo evaluation. J Microencapsul 2010, 27(3):226-233.
• [19]Maaben S, Schwarz C, Mehnert W, Lucks JS, Yunis-Specht F, Muller BW: Comparison of cytotoxicity between polyester nanoparticles and solid lipid nanoparticles. Proc Int Symp Control Rel Bioact Mater 1993, 20:490-491.
• [20]Yang SC, Zhu JB, Lu Y, Liang BW, Yang CZ: Body distribution of camptothecin solid lipid nanoparticles after oral administration. Pharm Res 1999, 16:751-757.
• [21]Mukherjee S, Ray S, Thakur RS: The current status of solid lipid nanoparticles. Pharmabit, XV 2007, 1:53-60.
• [22]Almeida AJ, Runge S, Muller RH: Peptide-loaded solid lipid nanoparticles (SLN): influence of production parameters. Int J Pharm 1997, 149:255-265.
• [23]Iveson SM, Litster JD, Hapgood KP, Ennis BJ: Nucleation, growth and breakage phenomena in agitated wet granulation processes: A review. Powder Technol 2001, 117:3-39.